No	REC Reference Number	IRAS No	Title	Date of First Patient Recruitment	Benchmark Met	Date site invited	Date site selected	HRA Approval date	Date site confirmed by sponsor	Date site confirmed	Date site ready to start	A - Permissions delayed/denied	B - Suspended by Sponsor	C - Closed by Sponsor	D - Sponsor delays	E - Staff Availability issues	F - No Eligible Patients (No patient seen)	G - No Patients Consented	H - Contracting Delays	I-Rare disease	J-Other	Comments	Sources of delay
1	15/EM/0551	191168	Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial (IRONMAN)		N/A	26/08/2016	01/06/2017	07/07/2016	16/05/2017	01/06/2017	02/06/2017											N/A as 70 day benchmark not exceeded at time of report period	
2	16/EE/0234	194284	Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study.		N/A	15/06/2016	25/05/2017	12/09/2016	25/05/2017	25/05/2017												N/A as 70 day benchmark not exceeded at time of report period	
3	16/EE/0370	198596	MesoTRAP: A feasibility study comparing video-assisted thoracoscopic partial pleurectomy/decortication with indwelling pleural catheter in patients with trapped lung and pleural effusion due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial.		N/A	16/12/2016	05/05/2017	11/01/2017	05/05/2017	09/05/2017												N/A as 70 day benchmark not exceeded at time of report period	
4	16/LO/1992	216381	Beyond education: A Hypoglycaemia Awareness Restoration Programme for people with type 1 diabetes and problematic hypoglycaemia persisting despite optimised self-care (HARPdoc)		N/A	18/01/2017	09/05/2017	10/01/2017	16/05/2017	22/05/2017	25/05/2017											N/A as 70 day benchmark not exceeded at time of report period	
5	16/NW/0517	188554	Accord Myeloma XII: A phase 3 study to determine the role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma.		N/A	10/05/2016	22/06/2017	27/10/2016	22/06/2017	22/06/2017	22/06/2017											N/A as 70 day benchmark not exceeded at time of report period	
6	16/SC/0484	208568	An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) CheckMate 651		N/A	04/01/2017	31/05/2017	10/02/2017	01/06/2017	12/06/2017	14/06/2017											N/A as 70 day benchmark not exceeded at time of report period	
7	16/WM/0514	213012	Accuracy of Detection using ENdocuff Optimisation of Mucosal Abnormalities: The B-ADENOMA Study		N/A	17/01/2017	28/06/2017	20/01/2017	28/06/2017	28/06/2017	28/06/2017											N/A as 70 day benchmark not exceeded at time of report period	
8	17/EM/0014	219556	Prospective Clinical Investigation for a Randomized, Controlled, Multicenter Non-inferiority Study Comparing Standard Wound Closure Technique with Drains (control) to Standard Wound Closure Techniques with TissuGlu® and No Drains (test) in Mastectomy.		N/A	13/04/2017	20/06/2017	10/03/2017	20/06/2017	23/06/2017	23/06/2017											N/A as 70 day benchmark not exceeded at time of report period	
9	17/LO/0243	219613	A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary biliary cholangitis. (GLIMMER: GSK2330672 triaL of Ibat inhibition with Multidose Measurement for Evaluation of Response)		N/A	09/03/2017	12/05/2017	27/03/2017	11/05/2017	23/05/2017												N/A as 70 day benchmark not exceeded at time of report period	

10	17/LO/0326	221071	Using Virtual Reality as a distraction technique to reduce pain during burn treatments.		N/A	07/02/2017	03/05/2017	24/03/2017	03/05/2017	04/05/2017													N/A as 70 day benchmark not exceeded at time of report period	
11	17/LO/0380	218003	A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of Crenezumab in patients with prodromal to mild Alzheimer's disease - Cread 2		N/A	05/01/2017	29/06/2017	18/05/2017	26/06/2017	29/06/2017	30/06/2017												N/A as 70 day benchmark not exceeded at time of report period	
12	17/NE/0115	218417	Multi-center, international, double-blind, two-arm, randomized, placebo-controlled phase II trial of pirfenidone in patients with unclassifiable progressive fibrosing ILD		N/A	07/12/2016	01/06/2017	26/05/2017	14/06/2017	23/06/2017	23/06/2017												N/A as 70 day benchmark not exceeded at time of report period	
13	17/YH/0083	220358	A randomised controlled trial of routine massage with a new lotion for the enhancement of skin health and cognitive development in infants		N/A	01/02/2017	08/06/2017	08/06/2017	15/06/2017	19/06/2017													N/A as 70 day benchmark not exceeded at time of report period	
14	15/SS/0225	169859	SYSTEMS-2: A Randomised Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma.	22/02/2017	No	18/01/2016	01/12/2016	05/10/2016	08/12/2016	09/02/2017	15/02/2017									Y			Contracting / costing delays with NHS Provider support service (Radiotherapy Physics)	NHS Provider
15	16/EE/0243	207331	A 6-month, multicenter, Phase 3, open-label extension safety study of OTO-104 given at 3-month intervals by intratympanic injection in subjects with unilateral Meniere's disease	06/02/2017	No	21/07/2016	25/11/2016	01/08/2016	25/11/2016	01/12/2016	06/02/2017				Y								Sponsor delayed confirmation of study open to recruitment at site	Sponsor
16	16/EE/0356	207367	A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn's Disease.		No	27/10/2016	27/02/2017	21/11/2016	28/02/2017	09/03/2017	18/05/2017				Y								Sponsor delayed confirmation of study open to recruitment at site.	Sponsor
17	16/EM/0193	190690	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial.	17/02/2017	No	11/03/2016	13/09/2016	14/06/2016	19/09/2016	28/09/2016	30/09/2016							Y					Patients screened but no eligible patients identified	Neither
18	16/EM/0376	211430	A 12-week, randomized, multi-center, double-blind, placebo-controlled, 3-arm, parallel-group, phase 3 trial to evaluate the efficacy and safety of 2 doses of AQX-1125 targeting the SHIP1 pathway in subjects with interstitial cystitits/bladder pain syndrome followed by a 2-arm, 14 or 40 week open label extension	09/05/2017	No	12/10/2016	12/01/2017	07/12/2016	07/02/2017	10/02/2017	10/02/2017							Y					Patients screened but no eligible patients identified until after 70 days had passed	Neither
19	16/EM/0384	182787	CV 185316: An Open-label, 2x2 Fractorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrilation and Acute Coronary Syndrome or Percutaneous Coronary Intervention	27/06/2017	No	25/08/2016	31/01/2017	21/11/2016	30/01/2017	01/02/2017	03/02/2017							Y					Strict patient eligibility criteria	Neither
20	16/LO/0913	186776	Corneal cross-linking versus standard care in children with keratoconus; a randomised, multicentre, observer-masked trial of efficacy and safety.	01/03/2017	No	25/08/2016	23/09/2016	04/08/2016	23/11/2016	28/11/2016	06/12/2016							Y		Y			Costing delays by NHS Provider. Patients screened but no eligible patients identified.	NHS Provider
21	16/LO/1004	207544	Modulation of immune response and outcomes in ALS using IL-2 (MIROCALS-IL2)		No	09/09/2016	16/03/2017	06/10/2016	21/03/2017	04/04/2017					Y								Sponsor delayed confirmation of study open to recruitment at site	Sponsor

22	16/LO/1138	207606	A Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD).		No	25/05/2016	10/11/2016	30/08/2016	10/11/2016	14/11/2016	16/11/2016						Y					Patients screened but no eligible patients identified. Strict patient eligibility criteria.	Neither
23	16/LO/1386	199366	Phase 2 Study: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of 7 Day Treatment with 'Elamipretide' in Patients Hospitalized with Severe Congestion due to Heart Failure.		No	07/06/2016	09/02/2017	14/11/2016	15/02/2017	20/02/2017	10/03/2017				Y		Y					Patients screened but no eligible patients identified. In addition, sponsor delayed confirmation of study open to recruitment at site.	Neither
24	16/LO/1697	212844	A Phase III randomised, controlled clinical trial of Pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy in subjects with advanced or metastatic urothelial carcinoma.		No	28/07/2016	08/11/2016	11/11/2016	11/11/2016	17/11/2016					Y							Sponsor delayed confirmation of study open to recruitment at site	Sponsor
25	16/NE/0238	204031	The British Heart Foundation older patients with non-ST Segment elevation myocardial infarction randomized interventional treatment trial	07/03/2017	No	01/09/2016	05/09/2016	08/08/2016	18/10/2016	07/10/2016	18/10/2016				Y							Sponsor delayed confirmation of study open to recruitment at site.	Sponsor
26	16/NE/0253	185463	Rituximab - a potential cure for the young patient with Graves' disease		No	07/04/2016	05/10/2016	22/09/2016	07/02/2017	17/02/2017	10/05/2017								Y			Contracting delays by Sponsor, further excaberated by incomplete funding information from Sponsor.	Sponsor
27	16/NE/0382	215735	A COMbined progRamme of exercise and dietary ADvice in mEn with castrate resistant prostate cancer - COMRADE trial	15/03/2017	No	31/10/2016	19/12/2016	18/01/2017	18/01/2017	23/01/2017	08/02/2017					Y						NHS Provider staff availability	NHS Provider
28	16/NI/0145	207927	Diabetic Macular Oedema and Diode Subthreshhold Micropulse Laser (DIAMONDS): A pragmatic, multicentre, allocation concealed, prospective, randomised, non-inferiority double masked trial	29/03/2017	No	23/09/2016	14/12/2016	29/11/2016	16/01/2017	01/02/2017	28/02/2017				Y				Y			Contracting delays by Sponsor and Lead Site, with participating sites. Sponsor delayed confirmation of study open to recruitment at site.	Sponsor
29	16/NW/0305	201856	A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study to Assess the Efficacy and Safety of one or more Intradetrusor Treatments of 600 or 800 Units of DYSPORT® for the Treatment of Urinary Incontinence in Subjects with Neurogenic Detrusor Overactivity due to Spinal Cord Injury or Multiple Sclerosis.		No	03/05/2016	19/10/2016	28/07/2016	19/10/2016	24/10/2016	24/10/2016					Y						NHS Provider staff availability	NHS Provider
30	16/NW/0396	191940	Very Low Dose Dexamethasone versus Placebo For the Treatment of Ventilator Dependent Preterm Babies.		No	22/09/2016	24/10/2016	30/06/2016	16/02/2017	22/02/2017	13/03/2017								Y			Contracting delays by sponsor.	Sponsor
31	16/NW/0606	211110	A Phase II single-arm, open-label monotherapy clinical trial of Pembrolizumab (MK-3475) in locally advanced/metastatic renal cell carcinoma (mRCC) (KEYNOTE-427)		No	03/08/2016	11/11/2016	23/09/2016	14/02/2017	16/02/2017	08/06/2017				Y							Sponsor delay in provision of study documentation. Trust provided budget feedback to sponsor in October 2016 and Sponsor did not respond to this until January 2017.	Sponsor
32	16/NW/0620	206738	Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating The Efficacy And Safety Of Oral Vadadustat For The Correction Of Anemia In Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT – CORRECTION)		No	13/10/2016	08/03/2017	17/11/2016	08/03/2017	20/03/2017	17/05/2017				Y							Sponsor delayed confirmation of study open to recruitment at site until after 70 days had passed	Sponsor

33	16/SC/0147	183044	Randomised double-blind cross-over study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as third line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on dual therapy with metformin and a sulphonylurea.	22/03/2017	No	08/03/2016	13/12/2016	07/07/2016	14/12/2016	13/01/2017	20/02/2017				Y							Sponsor delayed confirmation of study open to recruitment at site	Sponsor
34	16/SC/0382	196261	Effect of the Prevena Incision Management System on Sternal Wound Edge Perfusion in Patients undergoing CABG with Bilateral Mammary Artery grafts	15/02/2017	No	27/06/2016	30/08/2016	30/08/2016	30/08/2016	30/08/2016	13/09/2016										Y	Delay in delivery of equipment from supplier.	Neither
35	16/SC/0439	199315	ACL Surgery Necessity in Non Acute Patients Comparison of the clinical and cost effectiveness of two management strategies for non-acute Anterior Ligament (ACL) injury: Rehabilitation versus surgical Reconstruction		No	23/02/2017	15/03/2017	16/11/2016	15/03/2017	10/04/2017	05/06/2017						Y					Patients screened but no eligible patients identified	Neither
36	16/SC/0606	216489	Acceptability and tolerability of magnetic assisted capsule endoscopy compared to gastroscopy	09/03/2017	No	24/10/2016	24/11/2016	25/01/2017	25/01/2017	25/01/2017	07/03/2017								Y		Y	Costing delays by Sponsor. Also, delays with manufacturer in Korea visiting STH to train staff.	Sponsor
37	16/WM/0197	202991	A multi-center, randomized, double-blind, placebo controlled, parallel group phase 2a study to assess the efficacy of RO5459072 in patients with primary Sjogren's syndrome.		No	04/04/2016	28/07/2016	07/07/2016	14/06/2016	28/07/2016	22/08/2016						Y					Patients screened but no eligible patients identified	Neither
38	16/WM/0359	211812	A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects with Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma.	23/02/2017	No	29/07/2016	12/10/2016	12/10/2016	17/10/2016	02/11/2016	17/11/2016				Y		Y					Sponsor delay in provision of equipment (scanner). Patients screened but no eligible patients identified.	Sponsor
39	16/YH/0186	200765	A phase 4 double-blind, randomized, placebo-controlled, multi-center study to evaluate the efficacy, safety and tolerability of mirabegron in men with overactive bladder (OAB) symptoms while taking the alpha-blocker tamsulosin hydrochloride for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).		No	29/04/2016	10/10/2016	11/08/2016	11/10/2016	26/10/2016	29/11/2016				Y							Sponsor delayed confirmation to study open to recruitment at site.	Sponsor
40	16/YH/0212	200145	Unilateral and Bilateral Neurodynamic Sliding Techniques as a Means of Treating Non-compressive Sciatic Leg Pain: A Pilot Study for a Randomised Controlled Trial	05/01/2017	No	27/06/2016	25/10/2016	25/10/2016	25/10/2016	25/10/2016	25/10/2016				Y							Sponsor delay as a result of a protocol amendment - change of venue of intervention.	Sponsor
41	16/YH/0234	197040	Treatment of poor-grade Subarachnoid Haemorrhage Trial 2 - TOPSAT2		No	08/09/2016	13/10/2016	13/07/2016	22/11/2016	01/12/2016	19/12/2016				Y				Y	Y		The main source of delay was due to rare disease group so not expected to recruit within 70 day benchmark. Other delays included contracting / costing delays with NHS Provider support services. Sponsor delayed confirmation of study open to recruitment at site.	Neither
42	16/YH/0450	213782	20150288: A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)		No	25/01/2017	25/01/2017	25/01/2017	08/02/2017	13/02/2017	15/02/2017						Y					Patients screened but no eligible patients identified.	Neither

43	16/YH/0454	211679	A prospective multi-centre observational study to evaluate the capabilities of a portable magnetocardiograph (MCG) device to rule-out acute coronary syndrome (ACS) in patients who present to the emergency department with chest pain symptoms consistent with ACS.	27/02/2017	No	01/02/2016	06/12/2016	06/12/2016	17/01/2017	11/02/2017	22/02/2017								Y			Contracting delays. Sponsor delayed returning signed contracts	Sponsor
44	17/LO/0046	220052	Evaluation of safety following Immune Tolerance Induction treatment with turoctocog alfa in patients with haemophilia A following inhibitor development in NN7170-4213 trial		No	10/02/2017	10/02/2017	15/02/2017	18/04/2017	20/04/2017	20/04/2017						Y				Y	Main source of delay was Sponsor delay in study set up as site was to be a later additional site. Patients screened but no eligible patients identified.	Sponsor
45	17/SC/0023	220276	A Phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with V565 in subjects with active Crohn's disease		No	11/01/2017	03/04/2017	08/02/2017	04/04/2017	10/04/2017	23/05/2017				Y		Y					Sponsor delayed confirmation of study open to recruitment at site. Patients screened but no eligible patients identified.	Sponsor
46	16/EE/0235	202344	A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment	21/12/2016	Yes	13/06/2016	17/10/2016	14/10/2016	20/10/2016	03/11/2016	23/11/2016												
47	16/EE/0463	214371	COMPLEEMENT-1: An open-label, multicentre, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease	26/04/2017	Yes	19/10/2016	20/02/2017	30/01/2017	22/02/2017	23/02/2017	28/03/2017												
48	16/EM/0279	208089	PIONEER-5: Efficacy and safety of oral semaglutide versus placebo in subjects with Type 2 diabetes and moderate renal impairment.	22/11/2016	Yes	05/08/2016	14/10/2016	13/09/2016	20/10/2016	26/10/2016	01/11/2016												
49	16/EM/0320	208246	A Randomized, Multicentre, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in combination with Atezolizumab or Atezolizumab-Placebo in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer who have Received Prior Trastuzumab and Taxane Base Therapy [KATE-2]	13/02/2017	Yes	24/01/2017	24/01/2017	15/11/2016	26/01/2017	07/02/2017	10/02/2017												
50	16/LO/1024	195085	Safety and efficacy of Belimumab After B cell depletion therapy in systemic LUPUS erythematosus [BEAT LUPUS]	02/02/2017	Yes	20/10/2016	19/12/2016	20/09/2016	05/01/2017	11/01/2017	20/01/2017												
51	16/LO/1385	204611	The PodPAD Project - To evaluate the introduction of a public health approach to Peripheral Arterial Disease (PAD) using National Centre for Sport and Exercise Medicine facilities.	04/11/2016	Yes	12/07/2016	02/09/2016	02/09/2016	05/09/2016	05/09/2016	05/09/2016												
52	16/LO/1794	213087	Safety, tolerability, and pharmacokinetics study of single and multiple subcutaneous doses of turoctocog alfa pegol in patients with haemophilia A	20/04/2017	Yes	17/01/2017	02/03/2017	19/12/2016	03/03/2017	06/03/2017	06/03/2017												

53	16/NE/0418	211187	A phase III multicentre randomised controlled trial to compare the efficacy of Robotically Assisted Radical Cystectomy (RARC) and intracorporeal urinary diversion with Open Radical Cystectomy (ORC) in patients with bladder cancer	06/06/2017	Yes	08/02/2017	10/05/2017	25/01/2017	10/05/2017	10/05/2017	12/05/2017												
54	16/NS/0056	207899	Comparing the usability of an electronic bladder diary and a paper bladder diary: a two-way crossover study	02/11/2016	Yes	07/06/2016	25/08/2016	25/08/2016	25/08/2016	25/08/2016	30/08/2016												
55	16/NW/0242	193020	A Phase 1, randomised, open-label, 2-cohort, cross-over study to evaluate the pharmacokinetics, safety, and tolerability of a native oral testosterone formulation (DITEST) in the fed and fasted state and compared to testosterone undecanoate in adult men with primary or secondary hypogonadism	03/11/2016	Yes	12/02/2016	30/09/2016	27/07/2016	04/10/2016	13/10/2016	13/10/2016												
56	16/SC/0351	205155	A Phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with previously treated unresectable locally advanced or metastatic colorectal adenocarcinoma.	09/12/2016	Yes	19/07/2016	14/10/2016	31/08/2016	08/11/2016	17/11/2016	29/11/2016												
57	16/SC/0391	208610	A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis.	12/04/2017	Yes	05/09/2016	24/02/2017	13/10/2016	24/02/2017	06/03/2017	15/03/2017												
58	16/WM/0391	193794	The reality of myoelectric prostheses: Understanding the impact of skill, uncertainties and delays on the control of myoelectric prostheses	07/06/2017	Yes	24/01/2017	30/03/2017	15/12/2016	03/04/2017	03/04/2017	27/04/2017												
59	16/WS/0154	205571	Occupational Therapy Environmental assessment and falls [OTIS]	02/02/2017	Yes	15/09/2016	09/01/2017	08/09/2016	31/01/2017	31/01/2017	31/01/2017												
60	16/YH/0169	202450	Multi-channel Stimulation for Post Stroke Spasticity (MUSTS): A randomised controlled cross over feasibility trial.	11/11/2016	Yes	01/04/2016	09/09/2016	31/05/2016	30/09/2016	30/09/2016	30/09/2016												
61	16/YH/0268	167968	BRAVO study 2: High grade Bladder cancer: A randomised controlled trial of Radical Cystectomy against intra-vesical immunotherapy – A feasibility study	27/10/2016	Yes	08/06/2016	01/09/2016	12/08/2016	13/09/2016	20/09/2016	14/10/2016												
62	16/YH/0284	207203	Feasibility Study to Investigate the Potential Reduction of Bone Mineral Density Loss in Spinal Cord Injured Patients Using Ekso Therapy	08/12/2016	Yes	26/06/2016	06/10/2016	06/10/2016	06/10/2016	06/10/2016	06/10/2016												
63	16/YH/0304	205964	Is it feasible to conduct a randomised controlled trial of pre-transplant exercise (prehabilitation) for multiple myeloma patients awaiting autologous stem cell transplantation?	14/10/2016	Yes	05/07/2016	01/09/2016	01/09/2016	02/09/2016	02/09/2016	02/09/2016												
64	16/YH/0315	210710	Elastography in the diagnosis of chronic pancreatitis.	07/12/2016	Yes	22/07/2016	05/10/2016	24/11/2016	25/11/2016	26/11/2016	29/11/2016												
65	16/YH/0377	209735	The use of a virtual reality headset for the treatment of visual vertigo symptoms.	25/01/2017	Yes	12/08/2016	22/11/2016	11/11/2016	09/01/2017	09/01/2017	09/01/2017												

66	16/YH/0393	200308	The Effect of Selenium Supplementation on Musculoskeletal Health in Older Women Double-blind, randomised, placebo-controlled trial	23/01/2017	Yes	24/08/2016	14/12/2016	14/12/2016	11/01/2017	11/01/2017	11/01/2017													
67	16/YH/0506	212039	A Randomized, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD	22/05/2017	Yes	10/01/2017	31/03/2017	22/02/2017	03/04/2017	11/04/2017	04/05/2017													
68	17/NS/0020	224422	Double blind randomised controlled trial of Remote Ischemic preconditioning in Multiple sclerosis	02/05/2017	Yes	28/12/2016	17/03/2017	17/03/2017	05/04/2017	05/04/2017	05/04/2017													
69	17/YH/0103	221203	Prolonged ENoxapariN in primarY Percutaneous Coronary Intervention; a Pilot Pharmacodynamic study (PENNY PCI)	14/06/2017	Yes	09/03/2017	23/05/2017	23/05/2017	12/06/2017	12/06/2017	12/06/2017													